


# MOLECULAR DIAGNOSTICS

## REVENUE OUTLOOK

There is a multi-billion-dollar market for molecular testing technologies. HPV testing is a key segment of the double-digit, multi-billion-dollar global molecular diagnostic testing market. Through 2028, molecular HPV testing will grow 6.6%—outpacing growth in several other notable molecular testing segments including HIV, STIs, and genetic/inherited diseases.




Source: *The World Market for Molecular Diagnostics, 12th Edition*

## CATEGORY TRENDS

### ONCOLOGY


In 2023, oncology molecular diagnostics, valued at over \$6 billion, dominate the market. Key segments include colon cancer screening, ISH/FISH, HPV, CTCs, and oncology assays, particularly companion diagnostics (CDx), the largest and fastest-growing segment.



Source: *Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028*

### GENOMICS

The single cell genomics industry is projected to grow at a CAGR of 27.1% from 2022 to 2027. Currently, consumables make up 75% of sales, with instruments and hardware accounting for the rest. However, by 2027, instruments and hardware are expected to slightly increase their share.




Source: *The Market for Single Cell Analysis in Genomics: Next-Generation Sequencing and Other Technology, 2023-2027*

### LIQUID BIOPSY

Asia Pacific holds 12% of the global liquid biopsy market. With rising cancer rates and healthcare spending, access to testing is increasing. New companies are entering, while established ones expand through regional offices and partnerships.


Global Liquid Biopsy Market Share, by Geographic Region



Source: *The Worldwide Market for Liquid Biopsy, 6th Edition*

### MOLECULAR POINT OF CARE

Most sales in the molecular point-of-care market are in respiratory tests, with a significant portion now including COVID in combo/multiplex tests. Growing test volumes also include healthcare-associated infections (HAIs), sexually transmitted infections (STIs), and other diseases.



Source: *The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition*

### RNA SEQUENCING TRENDS

The RNA sequencing market continues to offer potent tools with the potential to usher in significant transformations in healthcare in the foreseeable future. Over the past decade, there has been a remarkable surge in product launches, novel applications, and a rush of end-user labs eager to become major competitors in this \$2.6 billion industry.

#### 7 Trends to Watch in RNA Sequencing

- 1. Increasing Importance Across Disease Areas:** RNA sequencing is increasingly recognized as a valuable tool in various diseases, providing unique insights compared to DNA sequencing.
- 2. Expansion into Clinical Applications:** RNA sequencing advances clinical applications like therapeutics, vaccines, gene editing, and personalized medicine. Single-cell sequencing boosts clinical possibilities.
- 3. Impact of COVID-19:** COVID-19 accelerated RNA analysis, underlining its significance in healthcare.
- 4. Data Analysis and Technology Integration:** RNA sequencing relies on crucial data analysis, bolstered by AI and cloud computing.
- 5. Translation into Clinical Settings:** RNA sequencing is translating effectively into clinical applications, outpacing other research techniques.
- 6. Emergence of Next-Generation Sequencing (NGS) Technologies:** NGS, including RNA sequencing, now pervades life sciences, offering cost-effective experiments and expanding biomedical research.
- 7. Continuous Technological Enhancements:** Ongoing tech improvements boost RNA sequencing's performance and output, with prices gradually stabilizing after decreasing over time.

Source: *The Market for RNA Sequencing, 3rd Edition*

## GET IN TOUCH:

Are you looking for more comprehensive information on the molecular diagnostics market? Contact us [here](#) to learn more about our reports!